Ventripoint Diagnostics Ltd.TSXV: VPT

Ventripoint Announces Successful Completion of Annual Quality and Regulatory Audits

· Issued by Ventripoint Diagnostics Ltd. via TheNewswire

Summary by 6ix AI

Ventripoint Diagnostics Ltd., which applies AI to heart ultrasound imaging, completed its annual audits under the Medical Device Single Audit Program (MDSAP, a common framework for checking medical device compliance), the ISO 13485:2016 quality management standard for medical device makers, and the EU Medical Device Regulation (MDR 2017/745).

Key details

  • The company says the audits confirm its quality management system remains effective and conforms with the applicable requirements for developing and manufacturing its medical devices.
  • The MDSAP framework covers participating jurisdictions, including the United States and Canada.
  • The EU review was an MDR surveillance audit covering requirements including safety, performance, traceability and post-market surveillance (monitoring devices after they are sold).
  • The company says maintaining these certifications supports product development, manufacturing and international market access as it advances commercialization of its VMS+ cardiac imaging platform.
  • President and CEO Hugh MacNaught said the company also successfully completed a TÜV manufacturing audit in August.

6ix AI wrote this summary from the release below and checked it against the release.

Ventripoint Diagnostics Ltd.

Toronto, Ontario (September 24, 2026) – TheNewswire - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) today announced the completion of its annual quality and regulatory audits covering the Medical Device Single Audit Program (MDSAP), ISO 13485:2016 Quality Management System and the European Union Medical Device Regulation (MDR 2017/745).

The completion of the audits confirms the continued effectiveness of Ventripoint’s quality management system and its conformity with the applicable quality and regulatory requirements governing the development and manufacture of its medical devices in key international markets that are regulatory approved/cleared.

The successful audits are particularly relevant as Ventripoint continues to advance the commercialization of its VMS+ cardiac imaging platform and expand its activities across multiple markets. Maintaining these certifications provides an important foundation for ongoing product development, manufacturing and international market access.

The scope of the audits included:

Medical Device Single Audit Program (MDSAP): MDSAP provides a common framework for assessing compliance with medical device regulatory requirements in participating jurisdictions, including the United States and Canada. Successful completion supports Ventripoint’s ability to maintain its regulatory standing across these important markets through a coordinated audit process.

ISO 13485:2016: This internationally recognized standard establishes requirements for quality management systems applicable to medical device manufacturers. Ventripoint’s successful audit confirms the continued operation of a quality system designed to support consistent product performance, safety and manufacturing quality.

EU Medical Device Regulation (MDR 2017/745): Completion of the MDR surveillance audit supports Ventripoint’s continued conformity with applicable EU Regulation 2017/745 , including requirements relating to safety, performance, traceability and post-market surveillance.

“We are pleased with the successful completion of these audits, which provide further confirmation of the strength and maturity of Ventripoint’s quality and manufacturing processes,” said Hugh MacNaught, President and CEO of Ventripoint. “The successful TÜV manufacturing audit completed in August, together with this latest review of our quality management system, demonstrates that our processes are supporting both the continued development of VMS+ 4.0 and the requirements of an expanding commercial business. Maintaining rigorous quality standards across product design and development, manufacturing, production and software validation, and regulatory compliance is essential as we increase adoption of VMS+ and expand into additional markets.”

About Ventripoint Diagnostics Ltd.

Ventripoint is an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada.

For further information, please contact:

Hugh MacNaught

[email protected]

604-671-4201

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Copyright (c) 2026 TheNewswire - All rights reserved.

View original source (TheNewswire)Ventripoint Diagnostics Ltd. on 6ix

Story so far

Earlier from Ventripoint Diagnostics

Later from Ventripoint Diagnostics

All Ventripoint Diagnostics news releases